The medical and treatment-related findings demonstrated that menopausal status (p = 0.256), age during breast cancer diagnosis (p = 0.449), breast biopsy (p = 0.298), side of breast affected (p = 0.730), stage of breast cancer diagnosis (p = 0.875), breast cancer receptors (p = 0.554), chemotherapy (p = 0.364), radiotherapy (p = 0.881) and anti-hormone therapy such as the estrogen receptor modulator (Tamoxifen) or aromatase inhibitor (Letrozole and Anastrazole) (p = 0.399) had no significant association with lymphedema. This evidence concerns the gene CYP19A1 and lymphedema.